Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus.
Irini Gergianaki, Alessandra Bortoluzzi, George Bertsias
https://pubmed.ncbi.nlm.nih.gov/30527426/Actively Recruiting
Led by CytoCares Inc · Updated on 2025-09-17
32
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating CC312 in adults with moderate to severe systemic lupus erythematosus SLE in a Phase I randomized, double-blind, placebo-controlled trial. This study aims to assess the safety, tolerability, how the body processes the drug pharmacokinetics, immune response, and early signs of effectiveness of CC312 in patients who have active disease despite standard treatments. Participants will receive either a single intravenous dose of CC312 or placebo. After 21 days, if safety and tolerability are confirmed by investigators and the sponsor, participants may enter a phase of multiple intravenous doses. The study compares CC312 to placebo and carefully monitors responses during these dosing phases. During the trial, participants will be closely observed for adverse events over two years. Researchers will measure drug levels in the blood, immune cell counts, specific lupus-related antibodies, and disease activity scores. Safety assessments include monitoring for serious reactions and immune responses to CC312. This extended follow-up helps understand the drugs impact and participant safety over time.
CONDITIONS
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
C
CEO
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
CytoCares Inc
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At least 21 days for initial dosing phase, with additional dosing phase duration depending on safety assessments
Participants receive a single intravenous dose of either CC312 or placebo, followed by a 21-day observation period before potentially proceeding to multiple intravenous doses after safety confirmation.
1 initial dosing visit and multiple dosing visits depending on safety and tolerability
Duration - Up to 2 years
Participants are monitored for safety, efficacy, pharmacokinetics, and immunogenicity of the study drug for up to 2 years after treatment.
Regular visits during the follow-up period as scheduled by the study team
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Irini Gergianaki, Alessandra Bortoluzzi, George Bertsias
https://pubmed.ncbi.nlm.nih.gov/30527426/George C Tsokos
https://pubmed.ncbi.nlm.nih.gov/22129255/Irene B Murimi-Worstell, Dora H Lin, Hong Kan...
https://pubmed.ncbi.nlm.nih.gov/32611669/CytoCares Inc
Lead Sponsor